Screener
Theravance Biopharma TBPH Other Non-Current Assets
Other Non-Current Assets at other companies
Other financials
Where this comes from
Reported directly by Theravance Biopharma in its filing.
Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.
The source filing: Theravance Biopharma’s 10-Q, filed August 11, 2026.
- Filed
- Aug 11, 2026, 8:00 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-093773
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Property and equipment, net | 5,169 | 5,895 |
| Operating lease assets | 21,926 | 24,371 |
| Restricted cash | 836 | 836 |
| Other assets | 25,177 | 24,880 |
| Total assets | $469,770 | $485,570 |
| Liabilities and Shareholders' Equity | ||
| Current liabilities: | ||
| Accounts payable | $652 | $2,568 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Theravance Biopharma's other non-current assets?
- Theravance Biopharma (TBPH) reported other non-current assets of $25.18M in Q2 2026.
- How has Theravance Biopharma's other non-current assets changed year-over-year?
- Theravance Biopharma's other non-current assets decreased by 2.3% year-over-year, from $25.77M to $25.18M.
- What is the long-term trend for Theravance Biopharma's other non-current assets?
- Over 5 years (2020 to 2025), Theravance Biopharma's other non-current assets has grown at a 59.0% compound annual growth rate (CAGR), from $2.45M to $24.88M.
- What does other non-current assets mean?
- Long-term assets not classified in specific categories — a catch-all for miscellaneous non-current assets.
Ask your AI about Theravance Biopharma's other non-current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude